Item 2.02Results of Operations and Financial Condition.

bluebird bio, Inc. (the "Company" or "bluebird") intends to share with investors the amount of cash, cash equivalents and marketable securities it had on hand as of December 31, 2019. Although the Company has not finalized its financial results for the twelve months ended December 31, 2019, the Company currently anticipates that its cash, cash equivalents and marketable securities were approximately $1.24 billion as of December 31, 2019. This information is unaudited and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2019 and its results of operations for the twelve months ended December 31, 2019. The Company expects to announce its full results for the twelve months ended December 31, 2019 on or before March 2, 2020.

Item 7.01Regulation FD Disclosure.

bluebird will be conducting meetings with investors attending the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California beginning on January 13, 2020. As part of these meetings, the Company will present the slides furnished to this Current Report as Exhibit 99.1, which is incorporated herein by reference.

The information in this Current Report on Form 8-K pursuant to Item 7.01 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this Current Report.




Item 8.01Other Events.

On January 13, 2020, bluebird issued a press release announcing its launch in Germany of ZYNTEGLO (autologous CD34+ cells encoding ?A-T87Q-globin gene), a one-time gene therapy for patients 12 years and older with transfusion-dependent ?-thalassemia (TDT) who do not have a ?0/?0 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.

The full text of bluebird's press release regarding the announcement is filed as Exhibit 99.2 to this Current Report on Form 8­K and is incorporated herein by reference.

Item 9.01Financial Statements and Exhibits.



(d) Exhibits



Exhibit
  No.                                   Description
99.1        Slides presented to Investors furnished by bluebird bio, Inc. on
          January 13, 2020  .
99.2        Press release issued by bluebird bio, Inc. on January 13, 2020  .
104       Cover Page Interactive Data File (embedded within the Inline XBRL
          document)






                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses